| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Rosavin's mechanism of action is complex and involves multiple pathways. It has antidepressant and anxiolytic actions by balancing neurotransmitters. It acts as an adaptogen, enhancing the body's response to environmental stress. It also influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation. Its antioxidant activity is evidenced by its ability to scavenge DPPH radicals.
|
|---|---|
| ln Vitro |
In vitro, rosavin is a well-known glycoside antioxidant. It has been shown to scavenge DPPH radicals. Its activity is studied in cell culture models to understand its effects on neurotransmission and bone metabolism. It exhibits antidepressant, anxiolytic, and adaptogenic properties. Its purity is 99.89%. It is soluble in DMSO at 85 mg/mL.
|
| ln Vivo |
In vivo, rosavin has demonstrated antidepressant, adaptogenic, and anxiolytic effects in mouse models. It is eliminated quickly, with a terminal half-life of 2.1 ± 0.5 hours after intravenous administration. After oral administration, it is rapidly absorbed, reaching Cmax at 0.9 ± 0.6 hours. These pharmacokinetic properties are important for its in vivo efficacy.
|
| Enzyme Assay |
Cell-free assays for rosavin measure its antioxidant activity, such as its ability to scavenge DPPH radicals. Its molecular weight (428.43) and formula (C20H28O10) are confirmed by mass spectrometry. Its purity (99.89%) is confirmed by HPLC. Its solubility in DMSO (85 mg/mL) is documented. Its stability under various conditions is also studied.
|
| Cell Assay |
Cellular assays for rosavin are performed to study its effects on neurotransmitter balance and bone metabolism. Its neuroprotective and adaptogenic effects are studied in neuronal cell cultures. Its effect on osteoclastogenesis and osteoblast differentiation is studied in bone cell models. These assays help to elucidate its mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for rosavin are conducted in mouse models to evaluate its antidepressant, anxiolytic, and adaptogenic effects. Pharmacokinetic studies in animals measure its absorption, distribution, metabolism, and excretion. These studies are crucial for understanding its in vivo activity and potential therapeutic applications.
|
| ADME/Pharmacokinetics |
Rosavin has a molecular weight of 428.43 and a molecular formula of C20H28O10. It is a cinnamyl alcohol glycoside. It is soluble in DMSO (85 mg/mL). In vivo, it is rapidly absorbed after oral administration and eliminated quickly. It is distributed in extracellular fluid. It should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Rosavin is generally considered safe based on its long history of use in traditional medicine as part of Rhodiola rosea. No significant toxicity has been reported. Its safety is inferred from its adaptogenic properties. However, comprehensive toxicology studies are lacking. It is not an approved drug and is intended for research use.
|
| References |
|
| Additional Infomation |
Rosavin is an O-acyl carbohydrate. It has been reported to be found in Rhodiola crenulata, Rhodiola sachalinensis, and other organisms with relevant data. See also: Roots (parts) of Sedum species.
Rosavin is a bioactive cinnamyl alcohol glycoside found in Rhodiola rosea. It exhibits antidepressant, anxiolytic, and adaptogenic properties. It acts by balancing neurotransmitters, enhancing stress response, and influencing bone metabolism. It is a popular research compound for neuroscience and metabolic health applications. |
| Molecular Formula |
C20H28O10
|
|---|---|
| Molecular Weight |
428.4303
|
| Exact Mass |
428.168
|
| CAS # |
84954-92-7
|
| PubChem CID |
9823887
|
| Appearance |
White to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
709.1±60.0 °C at 760 mmHg
|
| Flash Point |
382.6±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
1.83
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
540
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C1[C@@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC/C=C/C3=CC=CC=C3)O)O)O)O)O)O
|
| InChi Key |
RINHYCZCUGCZAJ-IPXOVKFZSA-N
|
| InChi Code |
InChI=1S/C20H28O10/c21-12-9-28-19(17(25)14(12)22)29-10-13-15(23)16(24)18(26)20(30-13)27-8-4-7-11-5-2-1-3-6-11/h1-7,12-26H,8-10H2/b7-4+/t12-,13+,14-,15+,16-,17+,18+,19-,20+/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(E)-3-phenylprop-2-enoxy]-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~233.41 mM)
H2O : ~50 mg/mL (~116.71 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 20 mg/mL (46.68 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3341 mL | 11.6705 mL | 23.3410 mL | |
| 5 mM | 0.4668 mL | 2.3341 mL | 4.6682 mL | |
| 10 mM | 0.2334 mL | 1.1671 mL | 2.3341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
